Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,331 across all filing types
Latest filing 2023-12-21 Remuneration Information
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Photocure ASA - Share option grant
Remuneration Information Classification · 99% confidence The document announces the cancellation and re-issuance of share options to employees, including specific grants to primary insiders (CEO, CFO, VPs). This directly relates to executive and employee compensation/incentives, which falls under remuneration guidelines. While it mentions remuneration guidelines approved at the AGM, the core subject is the grant of options to insiders. This aligns most closely with Director's Dealing (DIRS) if it were insider trading, but since it is a planned grant under an incentive program, it is related to compensation structure. However, the specific mention of grants to primary insiders (executives) and the reference to remuneration guidelines strongly suggests a link to compensation disclosure. Given the options, 'Director's Dealing' (DIRS) is for personal transactions, which this is not. 'Remuneration Information' (DEF 14A) covers compensation for top executives. Since this is a specific grant of options to executives/insiders, it is a form of remuneration disclosure. If it were a general report on executive pay, DEF 14A would be perfect. Since it is a specific transaction involving insider compensation instruments, and there isn't a perfect 'Option Grant' code, we must choose the closest fit. Director's Dealing (DIRS) is for personal share transactions by directors. This is a grant, not a transaction by the director themselves in the open market, but it is an insider transaction related to their role. Given the context of executive compensation disclosure, DEF 14A (Remuneration Information) is a strong candidate, but DIRS often captures insider transactions broadly. Let's re-evaluate the definitions. DIRS is 'Report of personal share transactions by company directors and executives (insider trades)'. This is a grant, not a trade by the executive. DEF 14A is 'Report detailing compensation for top executives and directors'. An option grant is a key component of executive compensation. Therefore, DEF 14A is the most appropriate classification for a document detailing executive option grants. The document also mentions that primary insider notifications pursuant to MAR article 19 are attached, which are often related to insider transactions/holdings, but the main body is about the compensation plan execution.
2023-12-21 English
Photocure ASA - Share option grant
Remuneration Information Classification · 99% confidence The document announces a 'Share option grant' involving the cancellation and re-issuance of options to employees, including specific grants to primary insiders (CEO, CFO, etc.). This directly relates to the compensation and incentive structure for management and directors. While it mentions remuneration guidelines (related to DEF 14A), the core action is the granting of shares/options, which is a form of capital change or insider transaction. Since it details specific grants to primary insiders (executives), it strongly aligns with insider trading reports (Directors' Dealing - DIRS) or remuneration details (DEF 14A). However, the primary focus is the transaction itself (granting options) and the disclosure requirements under MAR Article 19 for primary insiders. Given the specific nature of reporting executive/director transactions, DIRS is a strong candidate. Alternatively, since it details compensation grants, DEF 14A is relevant. Since the document explicitly states 'Primary insider notifications pursuant to the market abuse regulation article 19 are attached,' and details the transaction, DIRS (Director's Dealing) is the most precise fit for reporting executive share transactions, even if they are options. If the document were purely about the overall compensation policy, DEF 14A would fit better. Since it's a specific transaction report for insiders, DIRS is chosen over the broader DEF 14A.
2023-12-21 English
Photocure ASA – Major shareholding disclosure
Major Shareholding Notification Classification · 98% confidence The document explicitly states it is a "Major shareholding disclosure" concerning a transaction by Briarwood Chase Management LLC, resulting in them controlling 15.42% of the company's outstanding share capital. This directly corresponds to the definition of a Major Shareholding Notification (MRQ), which covers changes in significant share ownership levels crossing thresholds. The document length is very short (707 chars), but the content is a direct notification of a shareholding change, not an announcement about the publication of a separate report, making MRQ the most precise fit over the general RNS fallback.
2023-12-11 English
SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy
Regulatory Filings Classification · 99% confidence The document is explicitly titled as a "Press release" from Photocure ASA, dated December 1, 2023. It announces that new evidence regarding Blue Light Cystoscopy (BLC) was presented at the "24th Annual Society of Urologic Oncology (SUO) meeting." The content focuses on the presentation of clinical data and study results, concluding with contact information for media and investor relations. This structure—announcing new data/results via a press release—is characteristic of an Earnings Release (ER) or a general announcement. Since it is announcing the presentation of clinical data/results rather than the full quarterly financial performance (10-K or IR) or a formal transcript (CT), and it is a direct announcement of results/findings, the most appropriate classification is Earnings Release (ER), which often covers significant operational or clinical milestones alongside or instead of pure financial figures in biotech/pharma contexts, or potentially Regulatory Filing (RNS) if it were less specific. Given the focus on new evidence and results presentation, ER is a strong fit, although it is not a standard quarterly financial report. However, since it is a press release announcing significant findings, and it is not a formal regulatory filing like 10-K or IR, ER is the best fit among the options for a significant company announcement detailing performance/results, even if clinical rather than purely financial. It is not a Report Publication Announcement (RPA) because it contains the substance of the announcement, not just a notice that a report is available.
2023-12-01 English
SUO 2023 Meeting: New Real World Evidence shows Significant Decrease in Risk of Bladder Cancer Recurrence with Blue Light Cystoscopy
Regulatory Filings Classification · 95% confidence The document is explicitly titled as a 'Press release' from Photocure ASA, dated December 1, 2023. It announces new clinical evidence presented at the '24th Annual Society of Urologic Oncology (SUO) meeting' regarding their Blue Light Cystoscopy technology. This type of announcement, detailing recent scientific findings or corporate news released to the public via a press release, typically falls under general Regulatory Filings (RNS) if no other specific category fits better. It is not a formal regulatory report (like 10-K or IR), an earnings release (ER), or a management discussion (MDA). Since it is a general announcement of scientific data presentation, RNS is the most appropriate general regulatory/news category.
2023-12-01 English
Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Hexvix in China
Regulatory Filings Classification · 100% confidence The document is explicitly titled as a "Press Release" and announces a significant corporate event: the acceptance of a New Drug Application (NDA) by the National Medical Products Administration (NMPA) for a partner's product. This type of announcement, detailing operational progress, regulatory milestones, and partnership updates, is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a specific, material announcement that is not a full financial report (like 10-K or IR), nor a transcript (CT), nor a management discussion (MDA), the most fitting category is Earnings Release (ER) if it accompanies periodic results, or Regulatory Filing (RNS) if it's a standalone material event. Given the context of a press release announcing a regulatory milestone, ER is often used for key updates, but RNS serves as the general regulatory announcement fallback. However, many material, non-financial-statement announcements fall under ER if they are timely updates. Since this is a major operational/regulatory update, and not a standard quarterly earnings summary, RNS is a strong candidate. Let's re-evaluate the definitions. ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This is not financial results. LTR is for 'Legal Proceedings Report'. This is a regulatory acceptance, not a legal proceeding. Given the nature of a press release announcing a specific regulatory milestone (NDA acceptance), and lacking a better fit among the specific operational/financial codes, RNS (General regulatory announcements and fallback) is the most appropriate classification for this type of material, non-periodic, non-financial-specific announcement.
2023-11-29 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.